OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Leukaemia Recurrent reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,669 reports · 50 co-occurring drugs

As of the last recalculation, Leukaemia Recurrent appears in 1,669 FAERS reports alongside 50 co-occurring drug terms. The strongest observed disproportionality signal is IMATINIB (PRR 88.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Imatinib11688.188.7
Fludarabine Phosphate19369.169.4
Cytarabine25863.263.4
Tretinoin4062.963.2
Busulfan7360.560.7
Blinatumomab4960.360.6
Thiotepa4357.657.9
Mercaptopurine6447.848.0
Imatinib Mesylate9042.542.6
Dasatinib9433.433.4
Alemtuzumab4831.831.9
Nilotinib6327.627.7
Voriconazole6326.826.9
Posaconazole3426.626.7
Posaconazole Delayed-Release2225.325.4
Azacitidine5523.923.9
Venetoclax10823.323.4
Cladribine1722.322.3
Voriconazole Injection3621.121.1
Vincristine Sulfate4620.120.1
Ganciclovir Sodium1619.019.1
Ganciclovir1518.418.5
Azacitidine For2618.118.1
Micafungin Sodium1217.817.8
Cyclophosphamide Injection, Solution21417.117.2
Cyclophosphamide21417.117.2
Cyclophosphamide For Injection21417.117.2
Etoposide9416.816.9
Cyclosporine13316.116.1
Pegaspargase1515.415.4
Filgrastim4515.315.3
Melphalan Hydrochloride3015.215.2
Amphotericin B1515.115.1
Hydroxyurea2414.314.4
Atovaquone812.412.5
Hydrocortisone Sodium Succinate912.012.0
Melphalan2011.111.1
Anti-Thymocyte Globulin (Rabbit)710.910.9
Methotrexate28510.010.0
Acalabrutinib99.39.3
Doxorubicin618.88.8
Deferasirox188.58.6
Sorafenib148.58.5
Bosutinib68.48.4
Acyclovir687.77.7
Bendamustine Hcl86.56.5
Romiplostim65.05.0
Obinutuzumab64.64.6
Ruxolitinib254.44.4
Vemurafenib44.24.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.